Infertility. Female infertility associated with anovulation
Conditions
Interventions
Intervention 1: Intervention group: Group A: a subcutaneous injection dose of GnRH agonist (decapeptil) 0.2 mg (made by Ronac company) and then a second dose of decapeptil 0.1 mg injected 12 hours aft
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 38 Years
Inclusion criteria
Inclusion criteria: Selection of women with PCOS based on ESHRE ASRM Rotterdam criteria Stimulation with GnRH antagonist protocol Age 20-38 years E2 concentration > 2500 international units on the trigger day Body mass index > 18 and < 30 Having an indication for IVF or ICSI Willingness to participate in the study
Exclusion criteria
Exclusion criteria: severe cause of male infertility Uterine anomalies Severe endometriosis metabolic disease (e.g. metabolic syndrome) Patients with hypogonadism, hypogonadotropism Patients with underlying diseases such as thyroid disease, hyperprolactinemia, Cushing's syndrome, ovarian and adrenal tumors, diabetes, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of mature oocyte. Timepoint: 34-36 hours after decapeptil injection. Method of measurement: Transvaginal ultrasound.;Number of retrieved oocytes. Timepoint: 34-36 hours after decapeptil injection. Method of measurement: Transvaginal ultrasound.;The number of blastocysts. Timepoint: Two weeks after administration of Decapeptil. Method of measurement: Abdominal ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive pregnancy test. Timepoint: 4 weeks after IVF. Method of measurement: Beta HCG test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Atena Khayambashi
Esfahan University of Medical Sciences
Outcome results
None listed